Evidence map›Paper›PMID 29344836›Full record

ArticlePathology oncology research : POR2020

Boost Irradiation Integrated to Whole Brain Radiotherapy in the Management of Brain Metastases.

Ágnes Dobi, Emese Fodor, Anikó Maráz, Zsófia Együd, Adrienne Cserháti, László Tiszlavicz, Zita Reisz, Pál Barzó, Zoltán Varga, Katalin Hideghéty

Abstract read
PubMed Publisher
In one paragraph

Article in Pathology oncology research : POR, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Efficacy and safety evaluation of combined therapies incorporating whole-brain radiotherapy in patients with brain metastases: a systematic review and meta-analysis.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2024
    Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Ágnes DobiDepartment of Oncotherapy, University of Szeged, Korányi fasor 12, Szeged, H-6720, Hungary. dobiagnes@gmail.com.
Emese FodorDepartment of Oncotherapy, University of Szeged, Korányi fasor 12, Szeged, H-6720, Hungary.
Anikó MarázDepartment of Oncotherapy, University of Szeged, Korányi fasor 12, Szeged, H-6720, Hungary.
Zsófia EgyüdDepartment of Oncotherapy, University of Szeged, Korányi fasor 12, Szeged, H-6720, Hungary.
Adrienne CserhátiDepartment of Oncotherapy, University of Szeged, Korányi fasor 12, Szeged, H-6720, Hungary.
László TiszlaviczDepartment of Pathology, University of Szeged, Állomás utca 1, Szeged, H-6725, Hungary.
Zita ReiszDepartment of Pathology, University of Szeged, Állomás utca 1, Szeged, H-6725, Hungary.
Pál BarzóDepartment of Neurosurgery, University of Szeged, Semmelweis utca 8, Szeged, H-6725, Hungary.
Zoltán VargaDepartment of Oncotherapy, University of Szeged, Korányi fasor 12, Szeged, H-6720, Hungary.
Katalin HideghétyDepartment of Oncotherapy, University of Szeged, Korányi fasor 12, Szeged, H-6720, Hungary.

Funding

Analytic Healthcare Quality User Information Programme of the National Research, Development and Innovation Fund, Hungarian Government VKSZ 12-1- 2013-0012
6 · The paper itself

Abstract

Our retrospective analysis aimed to evaluate the clinical value of dose intensification schemes: WBRT and consecutive, delayed, or simultaneous integrated boost (SIB) in brain metastasis (BM) management. Clinical data and overall survival (OS) of 468 patients with BM from various primaries treated with 10 × 3 Gy WBRT (n = 195), WBRT+ 10 × 2 Gy boost (n = 125), or simultaneously 15 × 2.2 Gy WBRT+0.7 Gy boost (n = 148) during a 6-year period were statistically analysed. Significant difference in OS could be detected with additional boost to WBRT (3.3 versus 6.5 months) and this difference was confirmed for BMs of lung cancer and melanoma and both for oligo- and multiplex lesions. The OS was prolonged for the RPA 2 and RPA3 categories, if patients received escalated dose, 4.0 vs. 7.7 months; (p = 0.002) in class RPA2 and 2.6 vs. 4.2 months; (p < 0.0001) in the class RPA 3 respectively. The significant difference in OS was also achieved with SIB. The shortened overall treatment time of SIB with lower WBRT fraction dose exhibited survival benefit over WBRT alone, and could be applied for patients developing BM even with unfavourable prognostic factors. These results warrant for further study of this approach with dose escalation using the lately available solutions for hippocampus sparing and fractionated stereotactic irradiation. The simultaneous delivery of WBRT with reduced fraction dose and boost proved to be advantageous prolonging the OS with shortened treatment time and reduced probability for cognitive decline development even for patients with poor performance status and progressing extracranial disease.

Indexed as

Cranial IrradiationRe-IrradiationAdultAgedAged, 80 and overBrain NeoplasmsDose Fractionation, RadiationFemaleHumansMaleMiddle AgedRadiotherapy DosageRetrospective StudiesSurvival AnalysisYoung Adult3 DCRTBrain metastasisIMRTSimultaneous integrated boostWBRT

Identifiers

PMID29344836

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.